Once regulatory approvals are obtained, taiba will make the therapy available to WHIM patients via a named-patient programme, which allows for the use of medicines approved in other nations for ...
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback